TY - JOUR
T1 - Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use
AU - Jackson, David J.
AU - Burhan, Hassan
AU - Menzies-Gow, Andrew
AU - Pfeffer, Paul
AU - Nanzer, Alexandra
AU - Garcia Gil, Esther
AU - Morris, Tamsin
AU - Tran, Trung N.
AU - Hirsch, Ian
AU - Dube, Sabada
N1 - Funding Information:
This study was funded by AstraZeneca.Conflicts of interest: D. J. Jackson reports speaker's fees from AstraZeneca, Boehringer Ingelheim, Novartis, Teva, and GlaxoSmithKline and has served as an advisory board member for AstraZeneca, Teva, GlaxoSmithKline, Sanofi/Regeneron, and Chiesi. H. Burhan has received speaker's fees from AstraZeneca, Chiesi, and GlaxoSmithKline; received grant funding from AstraZeneca; and has served as an advisory board member for Novartis. A. Menzies-Gow has attended advisory boards and is on the steering committee for AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, and Teva; received speaker's fees from AstraZeneca, Novartis, Roche, and Teva; participated in research with AstraZeneca, for which his institution has been remunerated; attended international conferences with Teva; and made consultancy agreements with AstraZeneca, Sanofi, and Vectura. P. Pfeffer has received speaker's fees and served as a researcher on clinical trials for AstraZeneca; has also participated in advisory boards for Novartis; has served as a clinical trial researcher for Novartis and GlaxoSmithKline; and has current grant funding from GlaxoSmithKline. A. Nanzer has received speaker's fees from AstraZeneca and Napp. T. Morris, T. N. Tran, I. Hirsch, and S. Dube are employees and stockholders of AstraZeneca. E. G. Gil was an employee of AstraZeneca at the time of the study.
Funding Information:
Conflicts of interest: D. J. Jackson reports speaker’s fees from AstraZeneca , Boehringer Ingelheim , Novartis , Teva, and GlaxoSmithKline and has served as an advisory board member for AstraZeneca , Teva, GlaxoSmithKline , Sanofi / Regeneron , and Chiesi . H. Burhan has received speaker’s fees from AstraZeneca , Chiesi , and GlaxoSmithKline; received grant funding from AstraZeneca; and has served as an advisory board member for Novartis . A. Menzies-Gow has attended advisory boards and is on the steering committee for AstraZeneca , GlaxoSmithKline , Novartis , Sanofi , and Teva; received speaker’s fees from AstraZeneca , Novartis , Roche , and Teva; participated in research with AstraZeneca , for which his institution has been remunerated; attended international conferences with Teva; and made consultancy agreements with AstraZeneca , Sanofi , and Vectura. P. Pfeffer has received speaker’s fees and served as a researcher on clinical trials for AstraZeneca; has also participated in advisory boards for Novartis; has served as a clinical trial researcher for Novartis and GlaxoSmithKline; and has current grant funding from GlaxoSmithKline . A. Nanzer has received speaker’s fees from AstraZeneca and Napp. T. Morris, T. N. Tran, I. Hirsch, and S. Dube are employees and stockholders of AstraZeneca. E. G. Gil was an employee of AstraZeneca at the time of the study.
Funding Information:
This study was funded by AstraZeneca .
Publisher Copyright:
© 2022 The Authors
PY - 2022/6
Y1 - 2022/6
N2 - Background: Benralizumab is an IL-5 receptor alpha–directed cytolytic mAb that depletes eosinophils, reducing exacerbations and oral corticosteroid (OCS) use, and improves asthma control for patients with severe eosinophilic asthma (SEA). Data on response in patients previously treated with other biologic therapies are limited. Objective: To describe real-world clinical outcomes with benralizumab for patients with and without prior biologic use for uncontrolled SEA. Methods: This retrospective study compared clinical outcomes before and after benralizumab initiation in adults with uncontrolled SEA with 3 or more asthma exacerbations in the previous 12 months or on maintenance OCS treatment. Outcomes included exacerbations, OCS use, patient-reported outcomes, and health care resource utilization, including emergency department visits and hospitalizations. Results: In all, 208 patients were enrolled, including 90 (43.3%) with previous experience with an alternate biologic for SEA. Benralizumab led to an 81% reduction in exacerbation rate, with 48% of patients with previous exacerbations experiencing none after 48 weeks. Overall, 67% of patients requiring baseline maintenance OCS achieved greater than or equal to 50% reduction in daily OCS dosage, and 53% eliminated maintenance OCS. Clinically meaningful improvements in patient-reported outcomes were seen, with response at 4 weeks predicting longer-term benefits. Health care resource utilization also decreased. Improvements were observed irrespective of previous biologic experience, fractional exhaled nitric oxide concentrations, atopic status, or other baseline characteristics. Conclusions: In a multicenter real-world setting, patients with uncontrolled SEA achieved substantial improvements in all clinical outcome measures with benralizumab irrespective of previous biologic use, atopic status, or baseline fractional exhaled nitric oxide concentration.
AB - Background: Benralizumab is an IL-5 receptor alpha–directed cytolytic mAb that depletes eosinophils, reducing exacerbations and oral corticosteroid (OCS) use, and improves asthma control for patients with severe eosinophilic asthma (SEA). Data on response in patients previously treated with other biologic therapies are limited. Objective: To describe real-world clinical outcomes with benralizumab for patients with and without prior biologic use for uncontrolled SEA. Methods: This retrospective study compared clinical outcomes before and after benralizumab initiation in adults with uncontrolled SEA with 3 or more asthma exacerbations in the previous 12 months or on maintenance OCS treatment. Outcomes included exacerbations, OCS use, patient-reported outcomes, and health care resource utilization, including emergency department visits and hospitalizations. Results: In all, 208 patients were enrolled, including 90 (43.3%) with previous experience with an alternate biologic for SEA. Benralizumab led to an 81% reduction in exacerbation rate, with 48% of patients with previous exacerbations experiencing none after 48 weeks. Overall, 67% of patients requiring baseline maintenance OCS achieved greater than or equal to 50% reduction in daily OCS dosage, and 53% eliminated maintenance OCS. Clinically meaningful improvements in patient-reported outcomes were seen, with response at 4 weeks predicting longer-term benefits. Health care resource utilization also decreased. Improvements were observed irrespective of previous biologic experience, fractional exhaled nitric oxide concentrations, atopic status, or other baseline characteristics. Conclusions: In a multicenter real-world setting, patients with uncontrolled SEA achieved substantial improvements in all clinical outcome measures with benralizumab irrespective of previous biologic use, atopic status, or baseline fractional exhaled nitric oxide concentration.
KW - Atopy
KW - Benralizumab
KW - Biologic
KW - Fractional exhaled nitric oxide
KW - Oral corticosteroids
KW - Patient-reported outcomes
KW - Real-world study
KW - Severe eosinophilic asthma
UR - http://www.scopus.com/inward/record.url?scp=85126286861&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2022.02.014
DO - 10.1016/j.jaip.2022.02.014
M3 - Article
C2 - 35202871
AN - SCOPUS:85126286861
SN - 2213-2198
VL - 10
SP - 1534-1544.e4
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 6
ER -